Study of LY4256984 for ALS in Previous Trial Participants
Treatments studied
Part of Brain & nervous system, Hormones & metabolism clinical trials.
This is a follow-up study for people with ALS who have already completed another Eli Lilly ALS treatment trial. Researchers want to continue testing a new drug (LY4256984) in people who tolerated the previous treatment well.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have finished a previous Eli Lilly ALS treatment study (including all treatment and observation periods)
- You did not permanently stop the previous study drug due to safety concerns
- You did not experience severe ALS progression (such as needing permanent breathing support) during the previous study
- You did not develop a serious unexpected side effect or new illness during the previous study that would make continued treatment unsafe
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This is a follow-up study for people with ALS (a disease affecting nerve and muscle control) who completed a previous trial called OWAA. Researchers want to test how a new experimental drug called LY4256984 affects the spinal fluid around your brain and spine, which may help them understand if it could slow disease progression.
This trial studies an experimental drug called LTX-002 for people with ALS. It aims to see if the drug is safe and can slow down the disease.
This study tests an experimental drug called PLL001 for people with ALS. It aims to see if the drug is safe and if it can slow the progression of the disease. You may be a good fit if you have been recently diagnosed and are still in the early stages of ALS.
This trial tests a new drug called TP04HN106 for people with ALS. It aims to see if it is safe and if it might slow down the disease. You may qualify if your breathing is still fairly good and you have been on a stable dose of riluzole.
This trial tests a new drug called VTx-002 to see if it is safe and tolerable for people with ALS. You may be able to join if you have had symptoms for less than 18 months and have a caregiver who can help.
This study uses a comprehensive analysis platform to better understand ALS (and related conditions) and help find ways to “remedy and eliminate” it. If you have ALS or are a healthy control who can safely complete questionnaires and possibly an MRI, you may be able to contribute data that researchers use to improve care.
Hear when a new Amyotrophic Lateral Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.